Aware Super Pty Ltd as trustee of Aware Super Grows Stock Position in United Therapeutics Corporation $UTHR

Aware Super Pty Ltd as trustee of Aware Super grew its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 11.7% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 106,484 shares of the biotechnology company’s stock after purchasing an additional 11,172 shares during the quarter. Aware Super Pty Ltd as trustee of Aware Super owned approximately 0.24% of United Therapeutics worth $30,598,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in UTHR. Nuveen LLC purchased a new stake in United Therapeutics in the 1st quarter worth approximately $83,533,000. Amundi boosted its position in shares of United Therapeutics by 198.8% during the 1st quarter. Amundi now owns 350,193 shares of the biotechnology company’s stock valued at $107,635,000 after acquiring an additional 232,988 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of United Therapeutics by 1,657.8% during the 1st quarter. Acadian Asset Management LLC now owns 179,205 shares of the biotechnology company’s stock valued at $55,217,000 after acquiring an additional 169,010 shares during the last quarter. Invesco Ltd. boosted its position in shares of United Therapeutics by 46.1% during the 1st quarter. Invesco Ltd. now owns 465,115 shares of the biotechnology company’s stock valued at $143,381,000 after acquiring an additional 146,664 shares during the last quarter. Finally, Natixis Advisors LLC boosted its position in shares of United Therapeutics by 763.4% during the 1st quarter. Natixis Advisors LLC now owns 118,582 shares of the biotechnology company’s stock valued at $36,556,000 after acquiring an additional 104,847 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on UTHR shares. Bank of America lifted their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. UBS Group lifted their price objective on United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a report on Monday, September 29th. Morgan Stanley lifted their price objective on United Therapeutics from $328.00 to $435.00 and gave the company an “equal weight” rating in a report on Friday, October 10th. JPMorgan Chase & Co. reduced their target price on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a report on Tuesday, July 8th. Finally, Cantor Fitzgerald boosted their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. Ten equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $457.21.

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $440.35, for a total value of $9,907,875.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Martine A. Rothblatt sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $440.43, for a total value of $1,761,720.00. Following the completion of the sale, the chief executive officer owned 130 shares in the company, valued at approximately $57,255.90. This represents a 96.85% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 288,435 shares of company stock worth $117,231,067. Insiders own 10.30% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $432.19 on Thursday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $459.48. The firm has a market capitalization of $19.50 billion, a price-to-earnings ratio of 16.87, a PEG ratio of 4.73 and a beta of 0.66. The stock’s 50-day simple moving average is $380.39 and its 200-day simple moving average is $326.20.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. During the same quarter in the previous year, the firm posted $5.85 EPS. United Therapeutics’s revenue was up 11.7% on a year-over-year basis. As a group, equities analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.